An interventional study of Low-sodium salt substitute in Hypertension, sponsored by Johns Hopkins University. Recruiting at 1 site in Bangladesh. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Johns Hopkins University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Hypertension by Johns Hopkins University — 10 open to participants now, 14 under way, none of them phase 3. Hypertension · Johns Hopkins University.
Among the 50 studies in Hypertension by Johns Hopkins University, this one is the 7th largest by planned enrollment of the 44 interventional ones that give a count, is one of 7 that started in 2026, is one of 39 with no phase, reaches primary completion later than 3 of the 13 other live ones, and was the 46th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →10 of the 50 studies in Hypertension by Johns Hopkins University are open now, in 5 countries. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 21–70 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18–79 · Women only · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States, Ghana, Nigeria
Ages 18–70
Johns Hopkins University · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 607 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 138 across the 44 interventional studies, 50 across the 5 observational. Of the 33 that completed or were terminated, 8 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
7 of the studies in Hypertension by Johns Hopkins University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607341Johns Hopkins UniversityCommunity Engagement Alliance Against Disparities | 2026-12-20 |
| NCT06921356Johns Hopkins UniversityGroceries Plus Multi-Component Lifestyle Intervention for Adults With Hypertension and Type 2 Diabetes | 2027-03-31 |
| NCT07909161Johns Hopkins UniversityTeam-Based Shared Decision-Making Program in Hypertension Control (Healthy Heart - BP Program) | 2027-03-31 |
| NCT07460882Johns Hopkins UniversityThe Impact of Low Sodium Salt Substitute Use on Serum Potassium Levels Among Patients With Hypertension | 2027-03-31 |
| NCT05703386Johns Hopkins UniversityImaging the Pathogenesis of Cerebral Small Vessel Disease | 2027-03-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 50 studies in Hypertension by Johns Hopkins University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this pre-post study is to assess the risk of hyperkalemia in adults with hypertension on medication in Bangladesh. The main questions it aims to answer are:
Is the risk of hyperkalemia after the initiation of Low Sodium Salt Substitute (LSSS) in people on antihypertensive medication (especially RASi) large enough to be concerned about its broad use in this population?
Does initiation of LSSS correct hypokalemia in people on antihypertensive medication (especially RASi) with low serum potassium levels?
Participants will be asked to reduce overall salt intake and to use LSSS on every occasion where regular salt would normally be used, including as cooking salt.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants are asked to reduce overall salt intake and to use LSSS on every occasion where regular salt would normally be used, including as cooking salt
Dietary Supplement: Low-sodium salt substitute
The low sodium salt substitute contains 25% potassium chloride (KCl range; 20%-35%)
Incident hyperkalemia (K ≥5.5 mmol/L)
Time frame: 4 and 8 weeks
Proportion of the correction of hypokalemia (from K <3.5 mmol/L to 3.5-5.0 mmol/L)
Time frame: 4 and 8 weeks
Change in serum potassium levels
Time frame: 4 and 8 weeks
Change in systolic and diastolic blood pressure (mmHg)
Time frame: 4 and 8 weeks
Number of Participants Adherent to LSSS use
Time frame: 4 and 8 weeks
Plan to share: No — Individual participant data will not be shared due to institutional review board restrictions and participant privacy considerations.
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Mar 2027, 7 months after the start.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 7 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.